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ChronicB lymphocytic leukemia (B-CLL)' and multiple myeloma (MM) repre-
sent malignancies at different stages ofB cell differentiation . In B-CLL the majority
of the cells have characteristics of immature B lymphocytes, whereas in MM the
main part oftumorclone consists of end stage plasma cells (1-3). In both conditions,
the cells of the malignant clones express surface Ig with unique antigen binding parts
(idiotypes) (3-6).
Both B-CLLandMM patients can be divided into different subgroups . InB-CLL
a clinical staging system is used that vary from stage 0 to 4 (7, 8) and other factors
such as the isotype of the surface Ig, the expression of growth factor receptors, and
number of S-phase leukemic cells are clinically important (9-11) . InMM, the term
smoldering myeloma is used for a special type of benign MM (12, 13) .
In B-CLL there is evidence for abnormalities within theT and NK cell popula-
tions, (10, 14-17) . These changes may be part ofacellular response against the tumor
cells. In this paper we address this question by analyzing the occurrence of clonal
T cell populations in B-CLL andMM by probing for gene rearrangements repre-
sentative of theachain oftheTcell receptor loci (TCR) . Thepresence of such clonal
T cells may indicate a host response directed against leukemia-related antigens or
a special T-B cell interaction . We have foundevidence for predominantT cell clones
in 3/13 B-CLL patients and 1/8MM patients, all in comparatively clinical benign
stages .
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Materials and Methods
Diagnostic Criteria
Multiple Myeloma .
￿
The diagnosis of multiple myelomawas established if two or three of
the following criteria were met : (a) >10% plasma cells in aspirate of bone marrow specimens ;
(b) a myeloma globulin peak on serum and/or urine electrophoresis in association with de-
creased concentration of at least one nonmonoclonal serum Ig; and/or (c) osteolytic and/or
osteoporotic bone lesions demonstrated by x-ray examination of the skull, vertebral column,
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and pelvic bones(18). The clinical staging system for myeloma proposed by Durie and Salmon
was adopted (12).
SmolderingMultiple Myeloma.
￿
One patient (No. 14) fulfilled the criteria for smolderingmy-
eloma (13). At test this patient had been observed at the department for 4 yr. His condition
had remained stable. However, 6 mo after test his condition deteriorated and treatment was
instituted.
Chronic Lymphocytec Leukemia of B Cell Type (B-CLL).
￿
The main criteria for B-CLL was
infiltration in bone marrow of small lymphocytes and >10 x 109/liter of lymphocytes in pe-
ripheral blood showing restriction for is or A light chains (19). CLL patients were clinically
staged according to the staging system of Rai et al. (7). In this study a modification of the
criteria for stage 0 was used to define a truly clinically benign condition: no general symp-
toms (fever, night sweat, weight loss), no enlarged lymph nodes, no hepatosplenomegaly, no
anemia (Hb >120 g/liter), no thrombocytopenia (platelet counts >150 x 109/liter), and no
increase in lactodehydrogenase (LD <8.0 ukat/liter). Furthermore, during the observation
period no significant increase in the blood lymphocyte count (doubling of the lymphocyte
count) should have occurred. Moreover, no other symptoms or signs related to CLL should
be present during the follow up (20). The observation time for stage 0 B-CLL patients ranged
from 47 to 192 mo.
Isolation of Lymphocytes
Mononuclear cells were isolated on Hypaque density medium. Adherent cells were re-
moved by passage through nylon wool. T cells were isolated by panning of CD3' cells using
OKT3 antibody. All T cell populations were >95% pure.
Probe
The cDNA probe for detecting the T cell clonality is a generous gift from Dr. Tak W.
Mak (the Ontario Cancer Institute, Toronto, Ontario, Canada). It is a 770-bp fragment that
contains the J and C region of the human TCR S chain gene (20), and was labeled using
the commercial nick translation kit and [32p]dCTP (Amersham International Ltd., Amer-
sham, UK).
Southern Blot Analysis
DNA was extracted with phenol and chloroform, and electrophoresed through 0.7% agarose
gel after complete digestion with Eco RI and Barn HI (in some cases also with Hind III).
Southern transfer and hybridizations were performed according to a standard protocol (21).
After hybridization, the filters were washed twice in 2 x SSC, 0.2% SDS at room temperature
for 30 min and twice in 0.2 x SSC, 0.2% SDS at 65°C for 20 min. The autoradiograms were
developed after the exposure at -70°C for 2-4 d.
Results
13 patients with B-CLL and 8 patients with MM were studied. Eight ofthe B-CLL
patients were classified as stage 0 patients, a clinically benign condition with a good
prognosis (7, 8, 10). One of the MM cases was classified as a smoldering myeloma
(13) at time of testing, but later required treatment (case 14).
T cells were isolated from patients by using anti-CD3 antibodies on solid phase.
CD3 is a five-chain complex associated with TCR and a marker for mature T cells.
DNA extracted from patient T cells was analyzed on Southern blots and compared
with human germline, placental DNA. In four cases, evidence for T cell clonality
was found (cases 1-3 and 14) (Table I). In all these cases rearranged bands could
be seen in the Barn I digestions. In DNA from patients 1, 2, and 4, rearranged bands
can also be seen with Eco RI or Hind III digestions. This suggests rearrangements
in either the COI or the C/32 gene, as both these can be detected in Barn HI diges-WEN ET AL.
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TABLE I
Clinical Status and Presence of Clonal T Cell Populations in Patients
with B-CLL and Myeloma
tions while Eco RI and Hind III only detect single rearrangements of the Cl and
C2 loci, respectively .
Case 1 showed twoclones, both usingCß2 genes (Fig . 1) . Case2 showed onerear-
ranged band in theBamHI digestion, indicating one dominant T cell clone using
the Cß2 gene (Fig . 2) . Case 3 and 14 both had two rearranged bands in the Bam
HI digest, but only one band in the Eco RI digestion, indicating rearrangements
in the Cl locus (Figs . 3 and 4) .
Cases 1-3 were B-CLL patients in stage 0 and case 14 was a smoldering MM .
FIGURE 1. Case 1 . Two rearranged
bands were shown on both blots with
either Barn HI or Hind III digestion.
G, Germline DNA (from human
placenta) ; T, DNA from T cells.
Pat no . Diagnoses Sex Age
Clinical
stage
Totally
count
x 109/liter
Clonal
rearrangements
1 CLL F 72 0 14 .9 +
2 CLL F 63 0 38 .4 +
3 CLL F 75 0 14 .8 +
4 CLL M 70 0 12 .6 -
5 CLL M 69 0 18 .0 -
6 CLL F 72 0 81 .7 -
7 CLL F 71 0 24.4 -
8 CLL M 72 0 31 .5 -
9 CLL M 79 III 104 -
10 CLL M 68 III 25.2 -
11 CLL F 72 IV 40.0 -
12 CLL F 71 IV 86 .0 -
13 CLl M 72 IV 43 .5 -
14 Smoldering
myeloma M 57 - 1 .3 +
15 Myeloma M 61 IIIB 0 .8 -
16 Myeloma M 72 IIIA 1 .6 -
17 Myeloma F 78 IIIB 0 .7 -
18 Myeloma M 54 IIA 0 .9 -
19 Myeloma F 77 III 1 .2 -
20 Myeloma F 60 IA 1 .6 -
21 Myeloma M 78 IA 1 .6 -662
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FIGURE 2 .
￿
Case 2.Onerearranged band canbe
seen on the Bam HI blot . G, Germline DNA
(from human placenta) ; T, DNA from T cells .
FIGURE 3 .
￿
Case 3 . Two rearranged bands
are clearlyshownon the Barn HIblot, one
of them can also be seen on the Eco RI
blot . DNAfrom adherent B cells isolated
by nylon wool binding (lane B) show no
rearranged band . G, GermlineDNA(from
human placenta); T, DNA from T cells ;
B, DNA from B cells.
No patients with amore advanced disease had signs ofclonalT cell rearrangements,
suggesting that the level of clonal T cells may be <5%.
Discussion
In 3 of 13 B-CLL patients and 1 of 8 myeloma patients evidence was found for
a clonal predominance in the mature, peripheral T cell population . The method
used was based on the detection of specific rearrangements within in the gene for
theTCR,3 chain and has a sensitivity of 1-5% ofthe wholeT cell population (22) .
In othersystemswe have found that thedevelopment ofdetectable clones only occurs
with defined antigens presented by autologous cells . Thus, a substantial part of the
Tcell population in theB-CLL andmyeloma patients seemsto be involved in recog-
nition of certain restricted antigens, presumably expressed by the leukemic cells .
In patients with rheumatoid arthritis, T cells derived from synovial membranes,WEN ET AL .
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FIGURE 4.
￿
Case 14 . Two rearranged bands were
shown on the Bam HI blot with one of them on
the EcoRI blot. G, GermlineDNA (fromhuman
placenta); T, DNA from T cells.
and short-term tissue cultured in IL-2, have been found to contain apredominance
ofa limited number of clones by using the same technique as used in this report
(23). These cells may be reactive against autoantigens.
One potential class of antigens, whichmaybe involved in B lymphoproliferative
diseases, are idiotypesexpressed by thetumor cell related surface Ig (3-6) . However,
at present, we have no information regardingthe specificityoftheclonal Tcell popu-
lations, although in one case (No. 14), a short-term established T cell line could re-
spond byDNA synthesis when challenged with purified idiotype protein and autol-
ogous antigen-presenting cells(data to be published) . However, it cannot be excluded
that theclones were reactive againstnonleukemicantigens although no patientshad
any apparent infection at time of testing .
Clonal crosslineage rearrangements of the TCR fl chain can occur in B-type
leukemias, more commonly in B-CLL, than MM (24-30). However, we have sev-
eral reasons to believe that the clonality we have detected was present in theT popu-
lation rather than in monoclonal leukemic cells. First, mature T cells were isolated
by solid phase separation with anti-CD3 antibodies. CD3 is a marker for mature
T cells and only expressed by cells that express TCR at the cell surface . Second,
in at least one case (No . 14), the patient had no malignantB cells in the peripheral
circulation . Third, in three of the four cases with predominant clones, there was
evidence for two clones . This strongly suggests that these are T cell derived as leu-
kemiccells are clonal in nature (3). Fourth, in at leastone patient with predominant
clones, adherent leukemic cells that bound to nylonwool columns, were clearly negative
for rearrangements of the TCR (3 chain gene (Fig . 3) .
All patients with clonal predominance in theT cell population were clinically be-
nign cases, stage 0 B-CLL, or smolderingMM . This may indicate either that the
reactive clones are involved in the control of the leukemic cells and/or that the T
cell system is deregulated in more advanced cases . Some tumors areclearlyimmuno-
genicand an activehuman responsemay limit theirgrowth (31-33) . In experimental664
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B cell leukemias, isolated Ig idiotypes have been used to induce ahumoral and cel-
lular immune response againstthe corresponding leukemic cells(34, 35). Campbell
et al. (36) have synthesizedpeptides, corresponding to defineddeterminants binding
to the TCR, and found that such peptides also could induce a similar effect.
The reasons why a clonal T cell predominance was only detected in 4 of 21 cases
may be related either to a generalized T cell dysfunction or to properties ofthe leu-
kemic cells. We and others have found a progressive T cell imbalance in later stages
of B-CLL and myeloma, reflected by an inverted CD4/CD8 ratio and the appear-
ance of suppressor Tcells(3, 10, 12-14). These suppressor cellsmay disturb anormal
cellular immune response. In later stages the properties of the leukemic cells also
change. Onecharacteristic that maybe important, and that we recently have studied,
is the decreasedcapacity ofmore progressively growing B-CLLcells to secrete IL-1/3
(37). Stage 0 B-CLL cells secrete normal levels of IL-1(3 in vitro and they also ex-
press cell surface markers typical formyelomonocytic cells(38). Thus stage0 B-CLL
cells may be more active in antigen presentation, including processing of their own
antigens than leukemias in more advanced stages.
In summary, in some cases of benign B-CLL and MM, there are predominant
T cell clones present in the peripheral blood. Whether these clones are biologically
andclinically important is presently unclear. To study this question, the clones need
to be expanded in vitro, and characterized with regard to functional activity against
tumor cells.
Summary
Clonality in the non-neoplastic T cell population was investigated in 21 patients
with B cell chronic leukemic (B-CLL) or multiple myeloma (MM) by probing for
TCR 0 chain gene rearrangements using Southern blot analysis. In three patients
with a benign form of B-CLL (stage 0), and in one patient with smoldering MM,
evidence was found for predominant T cell clones. As cellular immunity against
the malignant cells maybe important in leukemia, the results are discussed in view
of the potential role of T cell immunity in B-CLL and MM.
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